Azurity Pharmaceuticals, Inc: FDA regulatory profile

Azurity Pharmaceuticals, Inc appears in 1 indexed U.S. FDA record: 1 drug-shortage entry (from 1 openFDA source row), naming 1 distinct product. Latest dated event: a shortage record dated 2026-08-20. Observations run 2020-04-10 to 2026-08-20 — 2323 days, 2 dated records across 2 calendar years, busiest 2026 with 1. Shortages: 1 current, averaging 1 package lines each across 1 FDA therapeutic category, 1 strength, 23 package NDCs and 2 brand names. 5 related firms and 4 adjacent shortage entries are linked below, each by a shared shortage entry, substance or therapeutic category. Every figure here is a count or a date computed from the indexed FDA datasets over a finite window: coverage-limited activity signals, never quality ratings or judgements about the firm. By year: 2026 (1), 2020 (1). Shortage entries include Dexmedetomidine Hydrochloride Injection (Current, since 2020-04-10, 1 lines). FDA therapeutic categories covered: Anesthesia. Strengths reported: 400 mcg/100 mL (4 ug/1 mL). Related firms include Accord Healthcare, Inc., Baxter Healthcare, HQ Specialty Pharma and Mylan Institutional, A Viatris Company. This firm appears in 1 indexed record, which is below the threshold this site requires before treating a manufacturer page as a standalone regulatory profile (only 1 indexed record). The page is published so the record remains reachable and verifiable, and it links on to the underlying FDA records, but it is marked noindex and left out of the sitemap: a single appearance of a company name is not a regulatory history, and presenting it as one would overstate what the data supports. Should further records reference this firm in a later ingestion, the page becomes a full profile automatically.